期刊文献+

高效液相色谱法测定阿维莫泮胶囊的含量 被引量:1

Determination of content of alvimopan capsule by HPLC
下载PDF
导出
摘要 目的:建立阿维莫泮胶囊的高效液相色谱(HPLC)含量测定方法。方法:液相分离采用SHIMADZUVPODS分析柱,柱温:30℃,以甲醇-0.05mol.L-1KH2PO4(pH2.8)溶液洗脱,流速为1.0ml.min-1,进样量20μl;检测波长:254nm;样品用流动相超声溶解,过滤后进样分析。结果:辅料及中间体均不干扰样品的测定;在5.0~1000mg·mL-1范围内阿维莫泮呈良好的线性关系,相关系数r=0.9999;回收率(n=9)为99.6%;日内和日间RSD均<1.0。结论:本方法操作简便、选择性好、准确、灵敏,可用于阿维莫泮的含量测定。 Objective:To develop a validated, highly sensitive and selective high performance liquid chromatographic (HPLC) method for the quantitative determination of alvimopan. Methods:After dissolve with mobile phase,20 p.l of sample solution was injected onto a Hypeersil ODS column and the effluont was measured for UV absorption at 254nm. A mixture of 0.01mol· L - 1 NaH2 po4 ( pH 3.0 ) - acetonitrile (75:25 ) was used as the mobile phase with the flow rate of 1.0mL min -1. Results :The linear concentration range for alvimopan was 5.0 - 1000mol · L - 1 ( r = 0. 9999 ), extraction recovery was 99.6% - 100.3% for alvimopan. The RSDs of intra - and inter - day were less than 1.0%. Conclusion:The method is sensitive and repeatable enough to be used in assay studies.
作者 刘红 刘存刚
出处 《医学信息(中旬刊)》 2010年第7期1670-1671,共2页 Medical Information Operations Sciences Fascicule
关键词 阿维莫泮胶囊 HPLC 含量测定 Alvimopan HPLC Determination
  • 相关文献

参考文献2

  • 1Bruce G.Wolff,Fabrizio Michelassi Todd M,et al.Alvlmopan,a Novel,Pe-ripherally Acting μ-Opioid Antagonist[J].Annals of Surgery,2004,240(4),728-735.
  • 2Eric L Marderstein,Canot P Dehney.Management of postoperative ileus:focus on alvimopan[J].Therapeutics and Clinical Risk Management,2008,4(5):965-973.

同被引文献8

  • 1William K Schmidt. Alvimopan (ADL 8-2698) is anovel peripheral opioid antagonist [J]. Am J Surg,2001,182(5) : 27s -38s.
  • 2Wolff BG, Michelassi F,Gerkin TM, et al, Alvi-mopan, a novel, peripherally acting mu opioid an-tagonist: results of a multicenter, randomized,double-blind, placebo-controlled . phase III trial ofmajor abdominal surgery and postoperative ileus[J].Ann Surg,2004,240(4) : 728 - 735.
  • 3Conor P. Delaney, James L. Weese,Neil H. Hy-man, et al. Phase III trial of alvimopan, a novel,peripherally acting,mu opioid antagonist, for post-operative ileus after major abdominal surgery [J].Dis Colon Rectum,2005 ,48(6) : 1114-1125.
  • 4Webster L,Jansen JP, Peppin J,et al. Alvimopan,a peripherally acting mu-opioid receptor (PAM-OR)antagonist for the treatment of opioid-induced boweldysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study insubjects taking opioids for chronic non-cancer pain[J]. Pain, 2008,137(2) : 428 - 440.
  • 5Beattie DT, Cheruvu M,Mai N, et al. The in vitropharmacology of the peripherally restricted opioidreceptor antagonists, alvimopan, ADL 08-0011 andmethylnaltrexoneCJ]. Naunyn Schmiedebergs ArchPharmacol,2007 , 375(3) :205 -220.
  • 6JF Foss,VD Schmith, B. Wallin,et al. Alvimopan(enteregTM) , a novel opioid antagonist, achievesactive systemic concentrations [ J ]. Clin PharmacolTher,2005,77(2): 74.
  • 7Foss JF, Fisher DM, Schmith VD. Pharmacokinet-ics of alvimopan and its metabolite in healthy volun-teers and patients in postoperative ileus trials [J].Clin Pharmacol Ther,2008 ,83(5): 770-776.
  • 8Schmith VD, Johnson BM, Vasist LS,et al. Theeffects of a short course of antibiotics on alvimopanand metabolite pharmacokinetics[J]. J Clin Pharma-col, 2010 .50(3) : 338-349.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部